Schroder Investment Management Group increased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) by 47.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 159,964 shares of the company’s stock after acquiring an additional 51,119 shares during the period. Schroder Investment Management Group owned approximately 0.08% of Recursion Pharmaceuticals worth $1,233,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of RXRX. Swiss National Bank grew its holdings in Recursion Pharmaceuticals by 7.6% in the first quarter. Swiss National Bank now owns 94,300 shares of the company’s stock valued at $675,000 after purchasing an additional 6,700 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Recursion Pharmaceuticals by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 373,700 shares of the company’s stock valued at $2,676,000 after purchasing an additional 6,294 shares during the last quarter. MetLife Investment Management LLC grew its holdings in Recursion Pharmaceuticals by 55.4% in the first quarter. MetLife Investment Management LLC now owns 64,035 shares of the company’s stock valued at $458,000 after purchasing an additional 22,833 shares during the last quarter. Rhumbline Advisers grew its holdings in Recursion Pharmaceuticals by 4.0% in the first quarter. Rhumbline Advisers now owns 123,892 shares of the company’s stock valued at $887,000 after purchasing an additional 4,818 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Recursion Pharmaceuticals by 8.1% in the first quarter. Vanguard Group Inc. now owns 6,611,377 shares of the company’s stock valued at $47,338,000 after purchasing an additional 497,504 shares during the last quarter. Institutional investors and hedge funds own 63.62% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have weighed in on RXRX shares. Morgan Stanley started coverage on Recursion Pharmaceuticals in a report on Monday, May 22nd. They issued an “equal weight” rating and a $8.00 target price on the stock. Needham & Company LLC started coverage on Recursion Pharmaceuticals in a research note on Thursday, March 16th. They set a “buy” rating and a $17.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $12.40.
Recursion Pharmaceuticals Stock Down 6.2 %
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) last released its earnings results on Monday, May 8th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.01. The firm had revenue of $12.13 million for the quarter, compared to the consensus estimate of $15.93 million. Recursion Pharmaceuticals had a negative return on equity of 57.15% and a negative net margin of 533.45%. As a group, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.41 EPS for the current fiscal year.
Insider Transactions at Recursion Pharmaceuticals
In other news, Director Blake Borgeson sold 8,885 shares of the firm’s stock in a transaction dated Tuesday, March 7th. The stock was sold at an average price of $8.33, for a total value of $74,012.05. Following the transaction, the director now directly owns 7,585,172 shares in the company, valued at approximately $63,184,482.76. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, COO Tina Marriott Larson sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 31st. The stock was sold at an average price of $8.63, for a total transaction of $25,890.00. Following the sale, the chief operating officer now directly owns 424,160 shares in the company, valued at approximately $3,660,500.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Blake Borgeson sold 8,885 shares of the firm’s stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $8.33, for a total value of $74,012.05. Following the sale, the director now owns 7,585,172 shares in the company, valued at $63,184,482.76. The disclosure for this sale can be found here. Insiders have sold a total of 173,600 shares of company stock worth $1,215,757 in the last three months. 22.25% of the stock is currently owned by company insiders.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.
Read More
- Get a free copy of the StockNews.com research report on Recursion Pharmaceuticals (RXRX)
- MarketBeat Week in Review – 5/29 – 6/2
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
- Constellation Brands Taps into Growth: Analysts Bullish on Stock
- CrowdStrike: Another Tech Stock to Buy on the Dip
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
